Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells

Cancer Gene Therapy

Volumn 9, Issue 3, 2002, Pages 296-307

  Scotlandi, Katia ^a   Maini, Cecilia ^a   Manara, Maria Cristina ^a   Benini, Stefania ^a   Serra, Massimo ^a   Cerisano, Vanessa ^a   Strammiello, Rosaria ^a   Baldini, Nicola ^a   Lollini, Pier Luigi ^b   Nanni, Patrizia ^b   Nicoletti, Giordano ^c   Picci, Piero ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Antisense; Ewing's sarcoma; Insulin like growth factor I; Malignancy; Nude mice

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BONE NEOPLASMS; DNA PRIMERS; DOWN-REGULATION; DOXORUBICIN; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, NUDE; NEOPLASM METASTASIS; POLYHYDROXYETHYL METHACRYLATE; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, ANTISENSE; RNA, MESSENGER; SARCOMA, EWING'S; TRANSFECTION; TUMOR CELLS, CULTURED;

COMPLEMENTARY DNA; DOXORUBICIN; NEUTRALIZING ANTIBODY; SOMATOMEDIN C RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; EWING SARCOMA; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALIA; MUS MUSCULUS;

EID: 85047699134     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700442     Document Type: Article

References (39)

1. The Ewing family of tumors - A subgroup of small-round-cell tumors defined by specific chimeric transcripts
2. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration
3. Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor
4. Long-term results in 144 localized Ewing's sarcoma patients treated with combined therapy
5. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II
6. Ewing's tumors with primary lung metastases: Survival analysis of 114 (European Intergroup) cooperative Ewing's sarcoma studies patients
7. Neoadjuvant chemotherapy for Ewing's sarcoma of bone. No benefit observed after adding iphosphamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase. Results of two sequential studies
8. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study
9. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor
10. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: A possible therapeutic target
11. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts
12. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice
13. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor
14. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor1 (IGF-1) receptors are nontumorigenic and induce regression of wild-type tumors
15. Real time quantitative PCR
16. A novel method for real time quantitative RT-PCR
17. A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding
18. Role of cell shape in growth control
19. Insulin-like growth factor-I-mediated survival from anoikis: Role of cell aggregation and focal adhesion kinase
20. Anti-apoptotic signaling of the IGF-I receptor in fibroblasts following loss of matrix adhesion
21. Basis for the acquisition of malignant potential by mouse cells cultivated in vitro
22. Murine model for skeletal metastases of Ewing's sarcoma
23. Type I and type II insulin-like growth factor receptors and their function in human Ewing's sarcoma cells
24. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma
25. Association of EWS/FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma
26. Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors
27. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor
28. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines
29. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo
30. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines
31. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo
32. The IGF-I receptor in cell growth, transformation and apoptosis
33. Activation of programmed cell death by anticancer agents: Cisplatin as a model system
34. Cell-cycle arrest versus cell death in cancer therapy
35. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis
36. Insulin-like growth factor 1 receptor overexpression mediates cellular resistance and local breast cancer recurrence after lumpectomy and radiation
37. Effect of the insulin-like growth factor 1 receptor on ionizing radiationinduced cell death in mouse embryo fibroblast
38. Insulin-like growth factor 1 (IGF-I) alters drug sensitivity of HBL 100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs